770 related articles for article (PubMed ID: 7728758)
1. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of natural killer cell-mediated bone marrow graft rejection by allogeneic major histocompatibility complex class I, but not class II molecules.
Ohlén C; Höglund P; Sentman CL; Carbone E; Ljunggren HG; Koller B; Kärre K
Eur J Immunol; 1995 May; 25(5):1286-91. PubMed ID: 7774631
[TBL] [Abstract][Full Text] [Related]
3. Role of major histocompatibility complex class I alpha 1/alpha 2 domain polymorphism and in vivo expression pattern in tumor resistance: studies with transgenic mice and lymphoma cell transfectants.
Höglund P; Waldenström M; Kärre K
J Immunother Emphasis Tumor Immunol; 1993 Oct; 14(3):175-81. PubMed ID: 8297899
[TBL] [Abstract][Full Text] [Related]
4. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
5. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
Chen PW; Ananthaswamy HN
J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect.
Morecki S; Yacovlev E; Gelfand Y; Vilensky A; Slavin S
Biol Blood Marrow Transplant; 2004 Jan; 10(1):40-8. PubMed ID: 14752778
[TBL] [Abstract][Full Text] [Related]
7. H-2Dp transgene alters natural killer cell specificity at the target and effector cell levels. Comparison with an H-2Dd transgene.
Sentman CL; Olsson-Alheim MY; Lendahl U; Kärre K
J Immunol; 1996 Apr; 156(7):2423-9. PubMed ID: 8786300
[TBL] [Abstract][Full Text] [Related]
8. Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth.
Campbell I; Moyana T; Carlsen S; Zheng C; Xiang J
Cancer Gene Ther; 2000 Jan; 7(1):37-44. PubMed ID: 10678354
[TBL] [Abstract][Full Text] [Related]
9. H-2 allele-specific protection from NK cell lysis in vitro for lymphoblasts but not tumor targets. Protection mediated by alpha 1/alpha 2 domains.
Sentman CL; Olsson MY; Salcedo M; Höglund P; Lendahl U; Käre K
J Immunol; 1994 Dec; 153(12):5482-90. PubMed ID: 7989750
[TBL] [Abstract][Full Text] [Related]
10. Influence of glycosylphosphatidylinositol-linked H-2Dd molecules on target cell protection and natural killer cell specificity in transgenic mice.
Sentman CL; Olsson-Alheim MY; Lendahl U; Kärre K
Eur J Immunol; 1996 Sep; 26(9):2127-32. PubMed ID: 8814257
[TBL] [Abstract][Full Text] [Related]
11. The ability of H-2Dd molecule to affect natural resistance to hemopoietic allografts is an intrinsic property shared by Ddm1 but not Ld.
Milisauskas VK; Nakamura I
Eur J Immunol; 1994 Feb; 24(2):336-42. PubMed ID: 8299682
[TBL] [Abstract][Full Text] [Related]
12. Role of endogenous peptides in murine allogenic cytotoxic T cell responses assessed using transfectants of the antigen-processing mutant 174xCEM.T2.
Crumpacker DB; Alexander J; Cresswell P; Engelhard VH
J Immunol; 1992 May; 148(10):3004-11. PubMed ID: 1374446
[TBL] [Abstract][Full Text] [Related]
13. Host MHC class I molecules modulate in vivo expression of a NK cell receptor.
Karlhofer FM; Hunziker R; Reichlin A; Margulies DH; Yokoyama WM
J Immunol; 1994 Sep; 153(6):2407-16. PubMed ID: 8077656
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of the rejection of bone marrow allografts by the depletion of activating versus inhibiting Ly-49 natural killer cell subsets.
Raziuddin A; Longo DL; Mason L; Ortaldo JR; Bennett M; Murphy WJ
J Immunol; 1998 Jan; 160(1):87-94. PubMed ID: 9551959
[TBL] [Abstract][Full Text] [Related]
15. CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells.
Monach PA; Schreiber H; Rowley DA
Transplantation; 1993 Jun; 55(6):1356-61. PubMed ID: 8100090
[TBL] [Abstract][Full Text] [Related]
16. H-40, an antigen controlled by an Igh-linked gene and recognized by cytotoxic T lymphocytes. II. Recognition of H-40 as a tumor antigen in leukemic animals.
Henderson LA; Ciavarra R; Riblet R; Forman J
J Immunol; 1984 Nov; 133(5):2778-85. PubMed ID: 6434638
[TBL] [Abstract][Full Text] [Related]
17. Adoptively transferred CD4+ lymphocytes from CD8 -/- mice are sufficient to mediate the rejection of MHC class II or class I disparate skin grafts.
Dalloul AH; Chmouzis E; Ngo K; Fung-Leung WP
J Immunol; 1996 Jun; 156(11):4114-9. PubMed ID: 8666777
[TBL] [Abstract][Full Text] [Related]
18. H-2Kb antigen expression has no effect on natural killer susceptibility and tumorigenicity of a murine hepatoma.
Nishimura MI; Stroynowski I; Hood L; Ostrand-Rosenberg S
J Immunol; 1988 Dec; 141(12):4403-9. PubMed ID: 3264312
[TBL] [Abstract][Full Text] [Related]
19. Fibrosarcoma cells expressing allogeneic MHC Class II antigens induce protective antitumor immunity.
Leach DR; Callahan GN
J Immunol; 1995 Jan; 154(2):738-43. PubMed ID: 7814880
[TBL] [Abstract][Full Text] [Related]
20. Murine Pam 212 cutaneous squamous cell carcinoma is nonimmunogenic in normal syngeneic hosts and resistant to immune effector mechanisms.
Chen Z; Rosten SI; Lord EM; Gaspari AA
Reg Immunol; 1993; 5(5):285-92. PubMed ID: 8148238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
